about
Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocolIn-patient costs of agitation and containment in a mental health catchment areaFactors affecting collaboration between general practitioners and community pharmacists: a qualitative study.New roles for pharmacists in community mental health care: a narrative review.Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study).Barriers and facilitators for the implementation of primary prevention and health promotion activities in primary care: a synthesis through meta-ethnography.Health service use and costs associated with aggressiveness or agitation and containment in adult psychiatric care: a systematic review of the evidence.Cost-effectiveness of active monitoring versus antidepressants for major depression in primary health care: a 12-month non-randomized controlled trial (INFAP study)Primary care patients' perspectives of barriers and enablers of primary prevention and health promotion-a meta-ethnographic synthesisAttitudes and intended behaviour to mental disorders and associated factors in catalan population, Spain: cross-sectional population-based survey.Setting-based interventions to promote mental health at the university: a systematic review.Effectiveness of pharmacist care in the improvement of adherence to antidepressants: a systematic review and meta-analysis.Adjustment disorders in primary care: prevalence, recognition and use of services.Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: a systematic review of cohort studies.Is there a case for mental health promotion in the primary care setting? A systematic review.Impact of initial medication non-adherence on use of healthcare services and sick leave: a longitudinal study in a large primary care cohort in Spain.Barriers for Nonparticipation and Dropout of Women in Cardiac Rehabilitation Programs: A Systematic Review.Use of Services and Cost of Agitation and Containment in Psychiatric Hospitals: a Systematic Review.Initial medication non-adherence: prevalence and predictive factors in a cohort of 1.6 million primary care patients.Loneliness and depression in the elderly: the role of social network.Effectiveness of Psychological and/or Educational Interventions in the Prevention of Anxiety: A Systematic Review, Meta-analysis, and Meta-regression.Multidimensional determinants of the caregiving burden among Chinese male caregivers of older family members in Hong Kong.Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.Functional Status, Quality of Life, and Costs Associated With Fibromyalgia Subgroups: A Latent Profile Analysis.Gender differences in the impact of mental disorders and chronic physical conditions on health-related quality of life among non-demented primary care elderly patients.Prevalence of mental disorders in non-demented elderly people in primary care [corrected].Beyond the consultation room: Proposals to approach health promotion in primary care according to health-care users, key community informants and primary care centre workers.Effectiveness of the "What's Up!" Intervention to Reduce Stigma and Psychometric Properties of the Youth Program Questionnaire (YPQ): Results from a Cluster Non-randomized Controlled Trial Conducted in Catalan High SchoolsCorrection: Cost-Effectiveness of a Community Pharmacist Intervention in Patients with Depression: A Randomized Controlled Trial (PRODEFAR Study).Psychotropic prescribing in Catalonia: results from an epidemiological study.Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: a randomized controlled superiority trial.Perceptions of collaboration between general practitioners and community pharmacists: findings from a qualitative study based in Spain.Comparing watchful waiting with antidepressants for the management of subclinical depression symptoms to mild-moderate depression in primary care: a systematic review.Prevalence and characteristics of catatonia on admission to an acute geriatric psychiatry ward.Impact of initial medication non-adherence to SSRIs on medical visits and sick leaves.Qualitative study of the agitation states and their characterization, and the interventions used to attend them.Corrigendum to: "Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: A randomized controlled superiority trial" [Eur. Neuropsychopharmacol. 23(2013)1057-1066].Impact of the mass media OBERTAMENT campaign on the levels of stigma among the population of Catalonia, Spain.Economic Impact of Third-Wave Cognitive Behavioral Therapies: A Systematic Review and Quality Assessment of Economic Evaluations in Randomized Controlled Trials.[Impact of pharmaceutical intervention in preventing relapses in depression in Primary Care].
P50
Q33490837-E8C1E336-FFE7-4B42-B3B3-8D7069C86D41Q33768186-2D532E44-450E-47F6-B3DC-E7E2B00A775BQ34329474-8AF115F1-5009-42C1-9742-01FDBD0E6593Q34412191-2F9C8599-758C-4CCF-B05B-B07DE0DCC2BAQ34947318-7E24EBA2-6B82-4896-8374-1200A6952394Q35107601-DC04F25B-BD20-457B-B460-E2912775753AQ35167081-31FB113C-A916-43A6-81D3-FAFF0ACA0BD2Q35380186-735F6EA9-27A0-4372-A968-FF487D0924E6Q35566325-9B44E975-096F-485D-A6B7-5A99973A03C9Q35919032-333892A3-66E1-4B6E-9B8E-1C47BC8A4CF6Q36065436-84FDD185-1CEF-470A-95A5-F5325ACE99E7Q37826021-66D27F90-7AB4-4CFC-807E-8330E4CFA658Q38009245-5F6EEAE7-93E9-40FA-97A0-FCE12FCABA1DQ38236631-9D42877C-4E8D-44BB-AC05-ADAC08D76118Q38283241-E6B9AED9-CBD1-4570-BCFF-640846254251Q38650936-60015802-1043-4950-B3B1-D2CC7C395DC6Q38733555-3F0B50A4-D259-469A-AA50-AF84D84C7C6BQ38839409-A4329FFB-AC39-4342-8D88-F8722F6E4636Q38946930-5980E44D-2207-4467-9508-557E76B6DBE4Q38982757-452D43C6-5F13-469E-8311-286BA374969CQ40055651-EE24E52B-BF62-428A-9D48-701B64BE809DQ40186722-00FD0D77-BBAD-4B56-B5F4-A1BFA058A3BBQ40684317-1EC196CC-D3B7-4774-A4D4-6461598C978DQ41075626-A30E2951-CE4F-401F-A4CB-0DB563DF26EAQ41108233-91AF713C-2A03-49F2-809C-1445ACEF3EAEQ41491913-35F1E9E6-F250-47AC-BFCB-80CAD59AD71BQ41642829-2ADF6038-D6AE-4103-BEC8-3C4080CF1A16Q41673480-0044C018-EBA4-4789-93B9-FD0F20D0B1FDQ43088139-717D74A0-B64A-4638-B7FB-BF5069ECE565Q43925019-F4C18EA2-F223-4860-A622-4A50A653F064Q43948444-06FB747A-BB5E-41C8-8A77-288524B228F3Q44528248-842A83BB-58E9-4409-98FF-CE617214D3EAQ47604513-92D92C82-EF2E-45C1-A3AD-6007EFE97DA8Q47716514-E940C6ED-28FB-4E25-9B93-A5A50D4CE051Q47741424-E875D389-D297-4FC6-A8E8-4E94C7E48849Q47934549-2DE11D05-A173-40D1-9D78-EF4D8B3D8256Q48055948-9AD699F3-BAE0-4287-B0C9-59F5CAEA364CQ49138746-71A70886-7F0F-451D-9E51-14E2FAB4F6D3Q50060083-348FAC88-5E2D-4A3A-9D6D-6470D8E2B99DQ50436405-49E56197-D014-4836-8237-88150FE39FB5
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maria Rubio-Valera
@ast
Maria Rubio-Valera
@en
Maria Rubio-Valera
@es
Maria Rubio-Valera
@nl
Maria Rubio-Valera
@sl
type
label
Maria Rubio-Valera
@ast
Maria Rubio-Valera
@en
Maria Rubio-Valera
@es
Maria Rubio-Valera
@nl
Maria Rubio-Valera
@sl
prefLabel
Maria Rubio-Valera
@ast
Maria Rubio-Valera
@en
Maria Rubio-Valera
@es
Maria Rubio-Valera
@nl
Maria Rubio-Valera
@sl
P1053
H-4840-2012
P106
P1153
34067858100
P21
P31
P3829
P496
0000-0003-2856-1697